Genentech, Inc.
NEWS
Genetech provides new data on the recently approved drug Enspryng. Continue with the article to know more about the recent updates about this drug.
August has been a busy month for the U.S. Food and Drug Administration. The final two weeks are marked by a number of PDUFA dates, although a few of those drugs have already been approved.
The U.S. Food and Drug Administration approved Genentech’s Enspryng (satralizumab-mwge) as a subcutaneous treatment for adults with anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder.
It was a very busy week for clinical trial updates. Here’s a look.
A Genentech investigational ulcerative colitis treatment etrolizumab posted mixed results in its late-stage study program in patients who have moderate or severe active forms of the disease.
Genentech, a Roche company, announced the U.S. Food and Drug Administration (FDA) had approved its Evrysdi (risdiplam) for spinal muscular atrophy (SMA) in adults and children two months of age and older.
Genentech’s checkpoint inhibitor Tecentriq combined with chemotherapy failed to hit the mark in a Phase III metastatic triple-negative breast cancer study.
Genentech is eliminating 474 employees, mostly based out of its South San Francisco facilities. The job cuts are expected to be permanent.
The drug is an investigational monoclonal antibody being developed for tauopathies like progressive supranuclear palsy (PSP) and Alzheimer’s disease.
JOBS
IN THE PRESS